{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-092128","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2026-08-06T21:15:10+00:00","discovered_at":"2026-08-06T21:16:00.588005+00:00","generated_at":"2026-08-06T21:16:08.706662+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aclaris Therapeutics enters into new at-the-market equity offering agreement with Leerink and Cantor","bullets":["Second Amended and Restated Sales Agreement with Leerink Partners and Cantor Fitzgerald for at-the-market common stock offerings.","Commission of 3.0% of gross proceeds payable to agents; no minimum offering amount required.","Replaces prior $100M ATM agreement dated February 27, 2025; new agreement has no stated maximum.","Shares sold under existing Form S-3 registration statement; Company retains discretion on timing and size."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-092128","json":"https://secwatch.observer/filing/0001104659-26-092128.json","markdown":"https://secwatch.observer/filing/0001104659-26-092128.md","text":"https://secwatch.observer/filing/0001104659-26-092128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926092128/0001104659-26-092128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926092128/acrs-20260806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T21:16:08.706662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}